Risk Factors Update Summary
- Accumulated deficit increased from $1.7 billion to $2.1 billion, impacting financial stability.
- Revenue from top five biopharmaceutical customers decreased from 27% to 14%.
- Medicare reimbursement rate for Guardant360 CDx test increased to match commercial rate.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1576280&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.